Design and Development of PLGA-PEG-FA Nanoparticles Encapsulating Noscapinoids for Receptor-Mediated Breast Cancer...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Folate receptors are overexpressed in breast cancer cells, making them a target for drug delivery.
• Anticancer agents like 9-bromo-noscapine (9-Br-Nos) can be effectively delivered using targeted nanocarriers.
• PLGA-PEG nanocarriers conjugated with folate offer a promising strategy for targeted cancer therapy.

Purpose of the Study:

• To synthesize and characterize folate-conjugated PLGA-PEG nanocarriers for targeted delivery of 9-bromo-noscapine.
• To evaluate the in vitro and in vivo anticancer efficacy of the nano-formulated drug.
• To investigate the mechanism of action of the nanocarrier system in breast cancer cells.

Main Methods:

• Synthesis and characterization of folate-conjugated PLGA-PEG nanocarriers.
• In vitro cytotoxicity and cellular uptake studies.
• Spheroid disintegration assay and Western blot analysis for apoptosis-related proteins.
• In vivo pharmacokinetic studies.

Main Results:

• Nanocarriers demonstrated efficient encapsulation and controlled drug release.
• Enhanced in vitro anticancer efficacy compared to free drug, with increased cellular uptake and ROS production.
• Significant tumor growth inhibition in 3D models and modulation of apoptosis-related proteins.
• Improved bioavailability and prolonged circulation time of the nano-encapsulated drug in vivo.

Conclusions:

• Folate-conjugated PLGA-PEG nanocarriers are effective for targeted delivery of 9-bromo-noscapine to breast cancer.
• The nanocarrier system enhances anticancer efficacy through improved cellular uptake, ROS generation, and apoptosis induction.
• This nanocarrier-based approach holds significant therapeutic potential for improving breast cancer treatment.